| |
NewswireTODAY - /newswire/ -
Leverkusen, Germany, 2017/10/20 - Saltigo at CPhI 2017, Frankfurt, October 24-26, Stand 111H21 - CPhI.com / Saltigo.com. FRA: DE Frankfurt: LXS
|
| |
Even more attractive to life science and fine chemical industries.
• Successful FDA audit GMP recertification;
• Saltigo keen to unlock new customer sectors;
• Process development, production and registration expertise.
Saltigo GmbH, a subsidiary of specialty chemicals company LANXESS, will be exhibiting at CPhI 2017 (cphi.com) as a flexible service-provider and one-stop supplier for the life science industries and users of fine chemicals. At the trade show in Frankfurt on October 24-26, 2017, the company will focus on its wide-ranging services for the exclusive synthesis of active chemical ingredients and intermediates.
Successful FDA audit GMP recertification
Independent assessments have been confirming the high quality of the services on offer. In summer 2017, Saltigo passed another audit by the U.S. Food and Drug Administration (FDA) with a “No findings” rating. The auditors inspected its production and quality assurance systems in Leverkusen over a period of four days. During an inspection of this kind, the FDA assesses whether a medical product can be manufactured at the company’s production facilities using technology that is recognized in the United States as complying with the state of the art and applicable cGMP (Current Good Manufacturing Practice) rules. The auditors also examined quality assurance systems and all facilities used from water treatment and clean rooms to filling plants and process control technology.
Shortly after this, in September 2017, the ultramodern multipurpose plant for manufacturing active pharmaceutical ingredients (APIs) and intermediates in Building O10 in Leverkusen obtained GMP (Good Manufacturing Practice) recertification. The official auditors did not have any objections. A total of over 200 metric tons of APIs and registered intermediates can be manufactured annually in the plant’s four production modules.
“The result of these two audits acknowledges all the work we have put in. They are internationally recognized quality criteria and show not just U.S. customers but also pharmaceutical companies throughout the world that with us the production of active ingredients is in safe and reliable hands,” says Saltigo’s head of Marketing and Sales Andreas Klein.
Saltigo keen to unlock new customer sectors
In addition to the wide range of GMP-related services, which are primarily aimed at regulated industries such as the pharmaceutical sector, Saltigo also sees the manufacture of ISO products as an important and attractive area of business. This includes activities such as the custom synthesis of regulatory starting materials i.e. starting materials for syntheses under GMP conditions and other precursors. “Our extensive process development expertise, together with the piloting and production options at ZeTO, our Central Organics Pilot Plant, make Saltigo an increasingly sought-after partner for new, chemically challenging syntheses,” says Saltigo’s head of New Business Development Guido Giffels. “The company’s broad technology base also offers attractive solutions in other fine chemical segments such as flavors and fragrances, performance chemicals or electronic chemicals. We are in the process of stepping up our involvement in these segments,” he adds.
Saltigo is currently implementing a major investment program to ensure its synthesis capacity remains at the cutting edge of technology and meets the needs of customer projects. Some EUR 60 million is being invested at the Leverkusen site for this purpose. The redevelopment and expansion work, mainly at ZeTO, is on schedule and is due for completion by the end of 2017.
Process development, production and registration expertise
“Standing still is equivalent to taking a step backward. This is also true of synthesis chemistry and process technology, which are constantly undergoing dynamic further development. It is important for us to keep on augmentingour project pipeline with new, innovative synthesis tasks from all chemical substance applications so as to be able to optimize the development and utilization of our technology portfolio and skills,” continues Giffels.
Saltigo is working on optimizing existing technical packages by improving space-time yields or simplifying processing sequences. It is also developing entirely new processes following consultation with its customers. This ensures that sufficient product volumes for requirements such as clinical trials of an active ingredient or other use tests are available quickly and reliably, with smooth upscaling to industrial volumes.
For example, Saltigo has developed a completely new synthesis route as an alternative to an existing pharmaceutical phase III project process that is difficult to implement. This new solution proved to be easily transferable to an industrial scale and also improves product quality. Saltigo has now successfully used this process to produce initial tons of the product for the market launch.
This is not the only example of Saltigo acting as a full-service provider in custom manufacturing. The LANXESS subsidiary’s service portfolio extends across the entire value chain from synthesis planning through process development and piloting to campaign planning, standard production and supply chain optimization in consultation with the customer. Saltigo can also help its customers with the registration of new substances. In this way, the company supports them all the way through to market readiness of the end products and beyond.
Saltigo GmbH (saltigo.com) is a leading supplier in the field of custom synthesis. The company of specialty chemicals group LANXESS belongs to the Advanced Intermediates segment, which achieved total sales in 2016 of EUR 1,742 million. Saltigo, headquartered in Leverkusen and with production facilities in Leverkusen and Dormagen, employs around 1,200 staff worldwide.
|
ilona.kawan[.]lanxess.com 
